| |
Access the latest, most trusted scientific, medical and academic research journals.
Click here
*Not all titles are enabled for PPV access.
Login To Trials & Price Quotes
Show Request Queue
|
|
Download a PDF version of this page
R&D Insight
Source: Adis International
| Coverage: |
1994 - Present |
| Data Type: |
Bibliographic with Full Text |
| Number of Records: |
23,000+ |
| Records Added Annually: |
8,000 updated annually, including both new records and updates to existing drug profiles |
Launched in 1995, Adis R&D Insight is a pipeline database of drug compounds. It is searchable by over 12 major fields allowing for finely-tuned, granular results.
Adis R&D Insight:
* Evaluates the strengths and weaknesses of competitors' pipelines
* Tracks drug compounds from development to product launch
* Analyzes potential threats to your market
* Identifies new business opportunities
* Reviews the commercial potential of a drug
* All significant updates delivered to the web daily
* In-depth profiles for 200+ pharmaceutical companies
* Full text of media releases highlighting commercial and scientific developments
* Powerful visual toolkit graphically illustrates pipeline data to view broad patterns
Adis R&D Insight has more than 23,000 in-depth profiles on drugs and research programs in development worldwide. These profiles are continuously monitored, and provide you with a comprehensive and powerful information resource for your market and competitor analysis. Each R&D Insight profile includes a detailed clinical and commercial overview of the products.
Adis’ team of in-house scientific editors continuously monitor the literature and scientific environment to develop objective, authoritative product profiles. This includes scientific meetings, direct company communications, annual reports, press releases and Internet sources.
Adis R&D Insight provides key product facts and developmental status worldwide. In addition, value-added benefits such as the Adis Rating of Therapeutic Value, the chemical structure, an extensive bibliography and commercial review, which includes financial projections licensed from Lehman Brothers. It is acclaimed for its comprehensive narrative clinical evaluations that are developed and expanded as the product moves through the pharmaceutical pipeline.
Broad Subjects:
Pharmacology; Business
Specific Subjects:
Business; Pharmaceuticals
|
|
| Search Databases By: |
|
| Industry & Association Info |
|
|
|
|
